EAU20 Virtual

The American Heart Association (AHA) has released its annual review of major scientific advances in cardiovascular research, citing significant progress in 2024 [1]. Here, we summarise a few of the key advances they name in their article, with essential reading referenced: 1.Rising cardiovascular disease burdenCardiovascular disease (CVD) prevalence is expected to rise from 11.3% to 15% of the U.S. population by…

https://conferences.medicom-publishers.com/wp-content/uploads/2024/12/ASH-podcast-2024.mp3In this episode [13:28], Medicom’s correspondent covers 6 presentations from annual meeting of the American Society of Hematology (ASH 2024), held in San Diego, CA, USA, from December 7-10, 2024.The topics discussed are: InMIND: Novel standard-of-care for relapsed or refractory follicular lymphoma?A treatment regimen of tafasitamab plus lenalidomide and rituximab outperformed lenalidomide plus rituximab and a placebo in patients with…

The interim analysis results of the EUROPA trial demonstrated a significant decrease in health-related quality of life (HRQoL) in elderly women with low-risk early-stage breast cancer (BC) treated with endocrine therapy (ET) compared with those receiving radiotherapy (RT), which demonstrated a favourable safety profile.Dr Icro Meattini (University of Florence, Italy) presented the interim analysis of the randomised, multicentre, non-inferiority, phase…

The phase 3 AFT-38 PATINA trial showed clinically meaningful improvement in progression-free survival (PFS) with the addition of palbociclib to anti-HER2 treatment and endocrine therapy (ET) in patients with HR-positive/HER2 metastatic breast cancer (mBC). “Around 25–30% of BCs are HER2-positive, with half of these co-expressing oestrogen receptors. Although anti-HER2 therapies have significantly improved outcomes in HER2-positive patients, resistance remains inevitable,”…

Although the ZEST trial was prematurely terminated due to insufficient enrolment of patients positive for circulating tumour DNA (ctDNA), it offered valuable insights, suggesting that ctDNA testing should be performed earlier in the treatment process rather than waiting until its completion.“Approximately 20–30% of early-stage breast cancer (BC) patients relapse, yet no standard of care exists to detect molecular residual disease…

Recent findings from the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) database revealed a continuous association between BMI and both distant recurrence rate and breast cancer (BC) mortality in early-stage BC, regardless of adjuvant systemic therapy, oestrogen receptor (ER) status, or tumour characteristics.Findings from the 2014 EBCTCG database (n=80,000) have shown a strong association between obesity and poor prognosis in…

Patients with intermediate-risk breast cancer (BC) showed comparable overall survival (OS) rates at 10 years in the SUPREMO trial, regardless of whether chest wall irradiation was used after mastectomy, which may have implications for clinical practice. The 10-year OS results of the randomised, phase 3 SUPREMO trial (NCT00966888) were presented by Prof. Ian Kunkler (University of Edinburgh, Scotland) [1]. “Based…

The EMBER-3 trial demonstrated the effectiveness of imlunestrant, both as monotherapy and in combination with abemaciclib, in patients with ESR1-mutated oestrogen (ER)-positive/HER2-negative advanced breast cancer (BC). Improved progression-free survival (PFS) and a favourable safety profile highlight the promising potential of imlunestrant for this patient group.The EMBER-3 trial (NCT04975308) was a phase 3, randomised, open-label study evaluating imlunestrant, a next-generation brain-penetrant…

In the phase 2 FASCINATE-N trial, neoadjuvant SHR-A1811 showed similar pathologic complete response (pCR) rates to the standard 4-drug regimen, with a tolerable safety profile in patients with HER2-positive breast cancer (BC).“Currently, the standard 4-drug regimen of paclitaxel, carboplatin, trastuzumab, and pertuzumab [PCbHP] is the preferred choice with pCR rates up to 65%. HER2-directed antibody-drug conjugates (ADCs), such as T-DM1…

After a median follow-up of 6.1 years, olaparib continued to demonstrate improved invasive disease-free survival (IDFS), distant disease-free survival (DDFS), and overall survival (OS) in high-risk BRCA1/2-mutated, HER2-negative breast cancer (BC) compared with placebo, according to the results of the OlympiA trial. Data from the third pre-specified interim analysis of the OlympiA trial (NCT02032823) were presented by Prof. Judy Garber…